Hodgkin Lymphoma SACT Regimens

Brentuximab vedotin and Bendamustine Therapy

Regimen

00529a

Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)

Brentuximab vedotin and Etoposide, methylPREDNISolone, Cytarabine and CISplatin therapy (BRESHAP)

Regimen

00530a

Treatment of adult patients with relapsed/refractory CD30+ Hodgkin lymphoma

Brentuximab vedotin and Ifosfamide, CARBOplatin and Etoposide (ICE) Therapy

Regimen

00528a

Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).

ChIVPP (Chlorambucil, vinBLAStine, Procarbazine, prednisoLONE) Therapy

Regimen

00452a

Treatment of patients with Hodgkin lymphoma who are unsuitable for anthracycline- or bleomycin-containing treatments or more intensive treatment

ESHAP Therapy

Regimen

00838b

Treatment of relapsed Hodgkin Lymphoma

Escalated Dose BEACOPP 21 day Therapy

Regimen

00354a

Treatment of patients with high risk, advanced stage Hodgkin Lymphoma (IPS ≥ 3)

00354b

Escalation of treatment of patients with Hodgkin Lymphoma after failure to reach complete metabolic response post 2 cycles of ABVD

Gemcitabine 1000mg/m2, Vinorelbine 20mg/m2 and Pegylated Liposomal DOXOrubicin 15mg/m2 (GVD) Therapy – Transplant Naive

Regimen

00853a

Treatment of relapsed or refractory Hodgkin’s lymphoma in transplant naïve patients

Gemcitabine 800mg/m2, Vinorelbine 15mg/m2 and Pegylated Liposomal DOXOrubicin 10mg/m2 (GVD) Therapy – Post Transplant

Regimen

00895a

Treatment of relapsed or refractory Hodgkin’s lymphoma in post-transplant patients

Pembrolizumab 200mg Monotherapy

Regimen

00455i

As monotherapy for the treatment of adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option

Nivolumab Monotherapy - 14 Day

Regimen

00483c

As monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.

Nivolumab - 28 day

Regimen

00484d

As monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.

Pembrolizumab 400mg monotherapy

Regimen

00558i

As monotherapy for the treatment of adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.

(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient

Regimen

00751b

Treatment of relapsed/refractory Hodgkin Lymphoma (HL)

riTUXimab, dexAMETHasone, Cytarabine and Oxaliplatin ((*R)-DHAOx) Therapy

Regimen

00834b

Treatment of relapsed Hodgkin’s Lymphoma

(R**)-DHAP Therapy

Regimen

00395b

Treatment of relapsed Hodgkin Lymphoma